StockData
Novartis AG logo

Novartis AG

NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Feb 4, 2026Score 7/30
$160.79−0.31 (-0.19%)

Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –

Novartis Aimovig (erenumab by Quarter

Aimovig (erenumab — migraine prevention Migraine) ($M)

QuarterlyAnnual

Novartis Aimovig (erenumab: $87M in Q3 2026, up 1.2% from a year earlier.

Latest, Q3 2026
87
Period ended Sep 30, 2026
Change on a year earlier
+1.2%
86 in Q3 2025
History
32 quarters
Since Q1 2018
Sources
24
Documents cited below

Where the Q3 2026 figure comes from

“|| Aimovig | 87 | 86 | 1 | 2”

Source: Novartis Form 6-K (0001114448-26-000014) ↗

Reported in Form 6-K & Form 20-F.

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAimovig (erenumab — migraine prevention Migraine) ($M)Year on yearSource
Q3 2026Sep 30, 202687+1.2%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2026Jun 30, 202688+6.0%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2026Mar 31, 202695+25.0%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2025Dec 31, 202590+12.5%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2025Sep 30, 202586+8.9%Novartis Form 6-K (0001114448-26-000014) ↗
Q2 2025Jun 30, 202583+7.8%Novartis Form 6-K (0001114448-26-000012) ↗
Q1 2025Mar 31, 2025760.0%Novartis Form 6-K (0001114448-26-000010) ↗
Q4 2024Dec 31, 202480+15.9%Novartis Form 6-K (0001114448-26-000007) ↗
Q3 2024Sep 30, 202479+14.5%Novartis Form 6-K (0001114448-25-000003) ↗
Q2 2024Jun 30, 202477+14.9%Novartis Form 6-K (0001370368-25-000012) ↗
Q1 2024Mar 31, 202476+24.6%Novartis Form 6-K (0001370368-25-000010) ↗
Q4 2023Dec 31, 202369+16.9%Novartis Form 6-K (0001370368-25-000007) ↗
Q3 2023Sep 30, 202369+38.0%Novartis Form 6-K (0001370368-24-000022) ↗
Q2 2023Jun 30, 202367+21.8%Novartis Form 6-K (0001370368-24-000019) ↗
Q1 2023Mar 31, 202361+13.0%Novartis Form 6-K (0001370368-24-000017) ↗
Q4 2022Dec 31, 2022590.0%Novartis Form 6-K (0001370368-24-000007) ↗

Breakdown

What makes up aimovig (erenumab

Cite this data

StockData. (2026). Novartis Aimovig (erenumab ($M), quarterly Q1 2018–Q3 2026 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-aimovig

See every metric in the Novartis KPI table. Data updated Nov 2, 2026.